CD38 and neoplasm: This regulation was pivotal in determining the responsiveness to ICB therapy, as tumor-reactive CD8+ T cells with genetic ablation of CD38 (Pmel-CD38−/− T cells) exhibited a robust anti-tumor response to anti-PD1 therapy; however, this effect was abrogated upon Tcf7 knockdown.